Skip to main content Deutsch


Sorry, this content is only available in German!

1. Identification of novel markers to predict response to anti-PD-1 immunotherapy in melanoma applying proteomics

  • serum glycoproteomics, serum depletion to enrich low abundant proteins using baseline serum samples (biobank USZ Prof. Levesque, samples of department of dermatology, MUW) of responder and non-responder to anti-PD-1 immunotherapy
  • application of high sensitive mass spectrometry (i.e. timsTOF) and different bioinformatic tools
  • quantification by selected reaction monitoring
  • functional assays and exosomal enrichment
  • clinical validation

2. Identification of drug resistance mechanisms to targeted and immune therapy by proteome characterisation of drug sensitive and resistant melanoma tumor cells or tissue

  • identification of a resistance signature
  • correlation of proteomics and RNAseq data
  • functional and clinical validation of the signature

3. Comprehensive analysis of proteomics, metabolomics and lipidomics in blood plasma of patients treated with Extracorporeal Photopheresis (ECP)

  • shotgun proteomics, metabolomics and lipidomics of serum samples before and after photopheresis for the evaluation of the acting mechanism
  • functional assays with different immune cells

4. Tumor Microenvironment

  • characterization of tumor associated fibroblasts and endothelial cells

Project in planning: Metabolomics and MS fingerprints of melanoma patients


Mass spectrometry:

Department of Analytical Chemistry , University Vienna, Prof Christopher Gerner and Joint Metabolome Facility (JMEF)

Institute of Molecular Systems Biology, ETH Zurich, Prof Ruedi Aebersold